Lakefront Biotherapeutics NV

Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

05 Jan 2026 16:01:00 By Nasdaq GlobeNewswire

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus

18 Dec 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

08 Dec 2025 01:30:00 By Nasdaq GlobeNewswire

Galapagos Receives Transparency Notifications from Bank of America

26 Nov 2025 01:30:00 By Nasdaq GlobeNewswire

Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

05 Nov 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

03 Nov 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

30 Oct 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

23 Oct 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation

21 Oct 2025 01:30:00 By Nasdaq GlobeNewswire

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

16 Oct 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business  

01 Oct 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos Creates New Subscription Right Plan

07 Aug 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

06 Aug 2025 01:30:00 By Nasdaq GlobeNewswire

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

23 Jul 2025 16:03:00 By Nasdaq GlobeNewswire

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

23 Jul 2025 16:02:00 By Nasdaq GlobeNewswire

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

23 Jul 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos Appoints Aaron Cox as Chief Financial Officer

23 Jun 2025 01:30:00 By Nasdaq GlobeNewswire

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

18 Jun 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

12 Jun 2025 16:01:00 By Nasdaq GlobeNewswire

Galapagos Creates New Subscription Right Plan

27 May 2025 16:33:01 By Nasdaq GlobeNewswire